Azenta, Inc. reported a revenue increase of 3.6% for the fiscal year ending September 30, 2025, reaching $593.8 million compared to $573.4 million in the previous year. The growth was primarily driven by the Sample Management Solutions and Multiomics segments, which saw revenue increases of 1.8% and 5.8%, respectively. Gross profit also improved, totaling $270.3 million, resulting in a gross margin of 45.5%, up from 44.4% in the prior year. Despite these gains, the company recorded a net loss of $55.8 million, a significant improvement from the $164.9 million loss reported in fiscal 2024, largely due to a reduction in losses from discontinued operations.
The company has undergone significant strategic changes, including the announcement of plans to sell its B Medical Systems business, which has been classified as a discontinued operation. This decision aims to streamline operations and focus on core segments. The B Medical Systems business generated $68 million in revenue for the fiscal year 2025, down from $83.1 million in 2024, and incurred a loss of $79.5 million, primarily due to an estimated loss on assets held for sale. Azenta's total employee count remains approximately 3,000, with operations spanning across North America, Europe, and Asia.
Operationally, Azenta reported a customer base of around 14,000, with 39% of total revenue generated from international sales, reflecting a slight increase from 36% in the previous year. The company continues to invest in research and development, with expenses totaling $30.4 million, a decrease from $31.5 million in fiscal 2024. Selling, general, and administrative expenses also saw a reduction, totaling $261.6 million, down from $263 million in the prior year. The company is actively pursuing cost-saving initiatives as part of its transformation plan, which is expected to yield long-term benefits.
Looking ahead, Azenta's management expressed optimism about future growth prospects, particularly in the life sciences sector, driven by increasing demand for genomic services and sample management solutions. However, the company acknowledged potential risks, including macroeconomic pressures, regulatory changes, and the ongoing need to enhance internal controls over financial reporting. The company has identified material weaknesses in its internal controls, which it is actively working to remediate. Despite these challenges, Azenta remains committed to leveraging its technological capabilities and expanding its market presence to drive profitability and shareholder value.
About Azenta, Inc.
Azenta, Inc. provides comprehensive biological and chemical sample management and genomic services for the life sciences industry. Its core offerings include automated ultra-cold storage systems, sample repository services, genomic sequencing and synthesis, and temperature-controlled transport solutions. Serving pharmaceutical, biotechnology, research institutions, and healthcare markets globally, Azenta ensures sample integrity and accelerates therapy development through integrated cold chain, multiomics, and data-driven solutions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.